

Stephen B Hanauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3960803/publications.pdf>

Version: 2024-02-01

123
papers

30,372
citations

66234

42
h-index

25716

108
g-index

125
all docs

125
docs citations

125
times ranked

11816
citing authors

#	ARTICLE	IF	CITATIONS
1	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. <i>Lancet</i> , The, 2002, 359, 1541-1549.	6.3	3,835
2	Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2005, 353, 2462-2476.	13.9	3,500
3	A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease. <i>New England Journal of Medicine</i> , 1997, 337, 1029-1036.	13.9	3,152
4	Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2013, 369, 699-710.	13.9	2,114
5	Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial. <i>Gastroenterology</i> , 2007, 132, 52-65.	0.6	1,986
6	Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn's Disease: the CLASSIC-I Trial. <i>Gastroenterology</i> , 2006, 130, 323-333.	0.6	1,523
7	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2016, 375, 1946-1960.	13.9	1,316
8	Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. <i>Gastroenterology</i> , 1999, 117, 761-769.	0.6	1,045
9	Maintenance Therapy with Certolizumab Pegol for Crohn's Disease. <i>New England Journal of Medicine</i> , 2007, 357, 239-250.	13.9	1,033
10	Natalizumab Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2005, 353, 1912-1925.	13.9	880
11	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. <i>Gut</i> , 2007, 56, 1232-1239.	6.1	866
12	Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. <i>Annals of Internal Medicine</i> , 2007, 146, 829.	2.0	849
13	Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. <i>Inflammatory Bowel Diseases</i> , 2006, 12, S3-S9.	0.9	756
14	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , 2011, 60, 780-787.	6.1	750
15	A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1627-1632.	13.9	704
16	Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. <i>Gastroenterology</i> , 2014, 147, 618-627.e3.	0.6	607
17	Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 542-553.	2.4	582
18	Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: A 2-year trial. <i>Gastroenterology</i> , 2004, 127, 723-729.	0.6	442

#	ARTICLE	IF	CITATIONS
19	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016, 374, 1754-1762.	13.9	361
20	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 348-354.e17.	2.4	309
21	Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial. <i>American Journal of Gastroenterology</i> , 2005, 100, 2478-2485.	0.2	286
22	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	0.6	251
23	Effect of Allopurinol on Clinical Outcomes in Inflammatory Bowel Disease Nonresponders to Azathioprine or 6-Mercaptopurine. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 209-214.	2.4	206
24	Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 441-446.	1.9	202
25	Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. <i>American Journal of Gastroenterology</i> , 1993, 88, 646-9.	0.2	199
26	Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1660-1671.	0.6	175
27	Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1557-1564.e1.	2.4	157
28	IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 23-32.	0.6	149
29	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 139-147.	2.4	138
30	Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 65-77.	1.9	128
31	Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1525-1532.e1.	2.4	124
32	Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 927-935.	0.6	117
33	Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 578-590.e4.	2.4	94
34	Safety and Effectiveness of Long-term Allopurinol Thiopurine Maintenance Treatment in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 363-369.	0.9	89
35	Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease. <i>Drug Safety</i> , 1991, 6, 192-219.	1.4	65
36	Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 162-167.	0.6	63

#	ARTICLE	IF	CITATIONS
37	Medical therapy of ulcerative colitis. <i>Lancet</i> , The, 1993, 342, 412-417.	6.3	62
38	Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1120-1129.	0.6	59
39	Dose-Ranging Study of Mesalamine (PENTASA) Enemas in the Treatment of Acute Ulcerative Proctosigmoiditis: Results of a Multicentered Placebo-Controlled Trial. <i>Inflammatory Bowel Diseases</i> , 1998, 4, 79-83.	0.9	52
40	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 607-616.	0.6	50
41	Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1577-1585.	0.9	50
42	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
43	Inflammatory Bowel Disease and the Risk of Prostate Cancer. <i>European Urology</i> , 2019, 75, 846-852.	0.9	47
44	Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?. <i>Gut</i> , 2007, 56, 1181-1183.	6.1	44
45	Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. <i>Inflammatory Bowel Diseases</i> , 1998, 4, 79-83.	0.9	43
46	Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 306-317.	1.9	39
47	Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2001-2006.	0.9	39
48	Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases—A Clinical Practice Update: Commentary. <i>Gastroenterology</i> , 2019, 156, 36-42.	0.6	39
49	Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1092-1102.	1.9	38
50	Use of thiopurines in inflammatory bowel disease: an update. <i>Intestinal Research</i> , 2022, 20, 11-30.	1.0	38
51	Etolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 28-37.	3.7	37
52	Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?. <i>ACG Case Reports Journal</i> , 2017, 4, e112.	0.2	35
53	Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 219-228.	1.9	35
54	The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications. <i>Hepatology</i> , 2020, 72, 1127-1138.	3.6	29

#	ARTICLE	IF	CITATIONS
55	Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study. <i>International Journal of Cancer</i> , 2020, 147, 2735-2742.	2.3	28
56	Optimizing pharmacologic management of inflammatory bowel disease. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 595-607.	1.3	27
57	Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1304-1309.	0.5	25
58	Placebo Response Rate in Clinical Trials of Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1981-1990.	2.4	24
59	Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 710-719.	0.9	24
60	Nicotine in Ulcerative Colitis. <i>BioDrugs</i> , 1996, 5, 169-174.	0.7	23
61	Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010-2014. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000155.	1.1	23
62	OPO2 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S001-S002.	0.6	23
63	Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 205-206.	2.4	21
64	Drug-Induced Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1759-1779.	2.4	20
65	Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 816-825.	3.7	20
66	THE MANAGEMENT OF ULCERATIVE COLITIS. <i>Annual Review of Medicine</i> , 1995, 46, 497-505.	5.0	16
67	Early vs Late Use of Anti-TNF α Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1808-1818.	0.9	16
68	Inflammatory Bowel Disease Revisited: Newer Drugs. <i>Scandinavian Journal of Gastroenterology</i> , 1990, 25, 97-106.	0.6	14
69	Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety) <i>Tj ETQq1 1 0.784314 rgBT /O</i>	1.1	14
70	Positioning biologic agents in the treatment of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1570-1582.	0.9	13
71	Integrating Adolescents and Young Adults into Adult-Centered Care for IBD. <i>Current Gastroenterology Reports</i> , 2016, 18, 21.	1.1	13
72	Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape. <i>Current Gastroenterology Reports</i> , 2021, 23, 16.	1.1	13

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. <i>Reviews in Gastroenterological Disorders</i> , 2004, 4 Suppl 3, S18-24.	0.6	13
74	Oral or Topical 5-ASA in Ulcerative Colitis. <i>Digestive Diseases</i> , 2016, 34, 122-124.	0.8	12
75	Patient Perspectives on Medical Trauma Related to Inflammatory Bowel Disease. <i>Journal of Clinical Psychology in Medical Settings</i> , 2022, 29, 596-607.	0.8	12
76	Review article: drug-induced small bowel injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1370-1388.	1.9	12
77	Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 53-70.	0.3	11
78	Medical Management of Crohn's Disease: Treatment Algorithms 2009. <i>Digestive Diseases</i> , 2009, 27, 536-541.	0.8	10
79	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1345-1353.	0.6	9
80	Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn's disease: a systematic review. <i>Frontline Gastroenterology</i> , 2021, 12, 423-436.	0.9	8
81	Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1012-1018.	0.9	8
82	Clinical Experience with Tixocortol Pivalate. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1988, 2, 156-158.	1.8	7
83	Heading Back to the Trough (Levels of Biologics in IBD). <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 548-551.	2.4	7
84	COLAL-PRED Alizyme. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 1192-7.	2.3	7
85	Vitamin D Levels and Outcomes in Inflammatory Bowel Disease—Which is the Chicken and Which is the Egg?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 247-248.	2.4	6
86	Hyperacute Methotrexate Pneumonitis in a Patient With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, A29-A30.	2.4	5
87	5-ASA enema therapy. <i>Netherlands Journal of Medicine</i> , 1989, 35 Suppl 1, S11-20.	0.6	5
88	More Than a Tumor Marker—A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1271-1276.	0.9	4
89	Comment on "Anti-Adhesion Therapies and the Rule of 3 for Rare Events". <i>American Journal of Gastroenterology</i> , 2014, 109, 1083-1084.	0.2	3
90	Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1915-1934.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Primary Adenocarcinoma of an Ileostomy in Crohn's Disease. <i>ACG Case Reports Journal</i> , 2016, 3, e112.	0.2	3
92	Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1274-1281.	0.6	3
93	Which Diet for Crohn's Disease? Food for Thought on the Specific Carbohydrate Diet, Mediterranean Diet, and Beyond. <i>Gastroenterology</i> , 2021, 161, 798-800.	0.6	3
94	DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn's Disease in the SERENE studies. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i124-i125.	0.6	3
95	Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1603-1606.	0.9	3
96	The Role of Mesalazine in Crohn's Disease. <i>Scandinavian Journal of Gastroenterology</i> , 1990, 25, 56-59.	0.6	2
97	The Holy Grail, or Only Half Way There?. <i>Gastroenterology</i> , 2015, 148, 8-10.	0.6	2
98	A Never Ending STORI. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1034-1036.	2.4	2
99	Use of the Endoscopic Healing Index for Monitoring of Disease Activity in Patients With Crohn's Disease in the COVID Era. <i>Crohn's & Colitis 360</i> , 2020, 2, .	0.5	2
100	Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1291-1305.	0.9	2
101	No Butts About It: Put the Fire Out By Lighting Up. <i>Inflammatory Bowel Diseases</i> , 1998, 4, 326.	0.9	1
102	ACG PRESIDENTIAL INTRODUCTION. <i>American Journal of Gastroenterology</i> , 2015, 110, 4-5.	0.2	1
103	P343 Efficacy of ustekinumab in Crohn's disease at maintenance Week 56: IM-UNITI study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S274-S274.	0.6	1
104	Executive Summary of "Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States". <i>American Journal of Gastroenterology</i> , 2020, 115, 1362-1366.	0.2	1
105	No butts about it: Put the fire oiut by lighting up. <i>Inflammatory Bowel Diseases</i> , 1998, 4, 326-326.	0.9	1
106	P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i379-i380.	0.6	1
107	Aminosalicylates: old and new. <i>Mount Sinai Journal of Medicine</i> , 1990, 57, 283-7.	1.9	1
108	New therapeutic approaches. <i>Gastroenterology Clinics of North America</i> , 1995, 24, 523-40.	1.0	1

#	ARTICLE	IF	CITATIONS
109	Biologics in peri-operative management of Crohn's disease. <i>Acta Gastro-Enterologica Belgica</i> , 2001, 64, 191-2.	0.4	1
110	A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, , .	1.4	1
111	Potential Human Models of Infammatory Bowel Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1995, 9, 316-318.	1.8	0
112	Nonobstructing Crohnâ€™s disease. <i>Current Treatment Options in Gastroenterology</i> , 1999, 2, 134-143.	0.3	0
113	Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient. <i>Lancet, The</i> , 2017, 389, 1671-1672.	6.3	0
114	Targeting Crohn's disease. <i>Lancet, The</i> , 2017, 390, 2742-2744.	6.3	0
115	One manâ€™s trash-another manâ€™s treasure: fecal transplantation. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 623-625.	0.7	0
116	Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e114-e114.	0.9	0
117	Too Soon to Discard 5-ASAs?. <i>American Journal of Gastroenterology</i> , 2019, 114, 534-535.	0.2	0
118	Inflammatory bowel disease and the risk of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e17052-e17052.	0.8	0
119	Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 55-55.	0.8	0
120	P457 Long-term cumulative safety of ustekinumab in bionative patients with Crohnâ€™s Disease and Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i434-i435.	0.6	0
121	Crohn's disease therapy: step up or top down therapy. <i>Acta Gastro-Enterologica Belgica</i> , 2001, 64, 189-90.	0.4	0
122	Olsalazine was more effective than mesalazine in maintaining remission from ulcerative colitis. <i>ACP Journal Club</i> , 1992, 117, 68.	0.1	0
123	Review: Most current drugs improve active Crohn disease but do not prevent relapse. <i>ACP Journal Club</i> , 1992, 117, 69.	0.1	0